A data review by the independent Data Safety
Monitoring Board resulted in a recommendation for the BETonMACE
trial to continue as planned without any modification.
CALGARY, March 17, 2017 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) today announced
that the independent Data and Safety Monitoring Board (DSMB)
for the Company's Phase 3 BETonMACE trial in high-risk
cardiovascular disease (CVD) patients has completed a third planned
safety review and recommended that the study should continue as
planned without any modifications. The DSMB reviewed available
study data and noted that no safety or efficacy concerns were
identified. The DSMB will conduct additional periodic reviews and
will also perform a futility assessment once 125 adjudicated major
adverse cardiac events (MACE) have been observed. Resverlogix, the
clinical steering committee, and all investigators remain blinded
to the trial data.
"Consistent with the two previous DSMB reviews, this third
review and recommendation of the DSMB to continue as planned in
BETonMACE permits the trial to remain on schedule. We have now
enrolled more than 1,200 patients in BETonMACE and apabetalone
remains well-tolerated with a consistent safety profile," stated
Dr. Michael Sweeney, M.D., Senior
Vice President of Clinical Development.
Filing of Quarterly Financial Statements and Management's
Discussion & Analysis
The Company has filed its unaudited interim Consolidated
Financial Statements and related Management's Discussion &
Analysis for the quarter ended January 31,
2017, with Canadian securities regulatory authorities.
Copies of these documents may be obtained online at www.sedar.com,
or the Company's website, www.resverlogix.com, or by emailing
ir@resverlogix.com.
Upcoming Conference Participation
Resverlogix is planning to participate in the following industry
conferences in the months of March and April.
•
|
ACC.17, American
College of Cardiology - 66th Annual Scientific Session &
Expo
|
|
|
|
|
Location:
|
Washington,
DC
|
|
Date:
|
March 17th
– 19th, 2017
|
|
Presentation
Info:
|
11:00 – 11:10 (EDT),
March 17th, Vascular Medicine Moderated
Poster
Theater, Poster Hall,
Hall C
|
|
Poster:
|
"Apabetalone
(RVX-208) Lowers Cardiovascular Disease (CVD) in
Diabetes Mellitus
by a Mechanism Involving Microbiome Mediated
Activity on the
Complement Pathway"
|
|
|
|
•
|
BIO-Europe
Spring
|
|
|
|
|
Location:
|
Barcelona,
Spain
|
|
Date:
|
March 20th
– 22nd, 2017
|
|
Presentation
Time:
|
9:30 (CET), March
21st
|
|
Presenting:
|
Mr. Donald J.
McCaffrey, President & Chief Executive Officer
|
|
|
|
•
|
AD/PD 2017,
13th International Conference on Alzheimer's &
Parkinson's Disease
|
|
|
|
|
Location:
|
Vienna,
Austria
|
|
Date:
|
March 29th
– April 2nd, 2017
|
|
Presentation
Info:
|
8:00 - 18:00 (CET),
March 29th
|
|
Presenting:
|
Dr. Ewelina
Kulikowski, Senior Vice President, Research &
Development
|
|
Poster:
|
"Apabetalone, a
BET Bromodomain Inhibitor, Suppresses Inflammatory
Mediators in
Microglia that Contribute to Neurodegenerative
Disease"
|
Resverlogix posters and presentations noted above will be made
available on the company website prior to their respective
presentation time.
- Posters will be available HERE.
- Company presentations will be available HERE.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, dialysis, Alzheimer's
disease, Orphan diseases, and peripheral artery disease, while
maintaining a well described safety profile. Apabetalone is the
only selective BET bromodomain inhibitor in human clinical trials,
currently in a Phase 3 trial BETonMACE in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the Company's Phase 3 clinical trial and
the potential role of apabetalone in the treatment of CVD, DM,
chronic kidney disease, Alzheimer's disease, Orphan diseases, and
peripheral artery disease. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR
at www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Resverlogix Corp.